GHAV (GHAV) Stock Price & Analysis
GHAV (GHAV) rose 0.00% to USD 0 as of June 10, 2026 at 05:11 UTC, according to Nexqual real-time market data.
GHAV last closed at USD 0; the session ranged USD 0–0 on volume of 44,100 shares. Market capitalization is $50,398, with a 52-week range of USD 0–0 (PNK). Source: Nexqual, June 10, 2026 at 05:11 UTC.
Key Statistics (as of June 10, 2026 at 05:11 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0 |
| Volume | 44,100 shares |
| Market Cap | $50,398 |
| Exchange | PNK |
Technical Analysis (GHAV)
Nexqual's technical model rates GHAV "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 05:11 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Below (USD 0) |
| MACD | 0 (negative) |
Analyst Ratings (GHAV)
Wall Street analysts rate GHAV "None", per Nexqual as of June 10, 2026 at 05:11 UTC.
| Consensus Rating | None |
|---|
Earnings (GHAV)
Source: Nexqual, June 10, 2026 at 05:11 UTC.
Financials & Fundamentals (GHAV)
| Total Revenue | $204,368 |
|---|---|
| Revenue Growth (YoY) | +90.70% |
| Gross Margin | +25.80% |
| Operating Margin | -1273.90% |
| Profit Margin | +0.00% |
| Current Ratio | 0.02 |
| Total Cash | $263,222 |
| Total Debt | $2.01M |
Source: Nexqual, June 10, 2026 at 05:11 UTC.
Financial Health Score (GHAV)
Nexqual rates GHAV's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 05:11 UTC.
| Growth | Strong — Revenue +91% YoY (latest Q) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $263K cash vs $2M debt |
| Cash Flow | Weak — Operating cash flow -$766K |
| Efficiency | Mixed — No data |
Ownership (GHAV)
| Insider Ownership | +63.73% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 503.98M |
Source: Nexqual, June 10, 2026 at 05:11 UTC.
Leadership (GHAV)
GHAV is led by Tanya Bredemeier, CEO & Director, per Nexqual as of June 10, 2026 at 05:11 UTC.
| CEO & Director | Tanya Bredemeier |
|---|---|
| COO & Director | Julio Sera |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| GXXM | GEX Management, Inc. | USD 0.11 | ▲ 5% |
| GSAC | GelStat Corp. | USD 0 | ▲ 0% |
| PACV | Pacific Ventures Group Inc. | USD 0 | ▲ 0% |
| AOXG | Aoxing Pharmaceutical Company, | USD 0 | ▼ 19.23% |
| CCWF | Church & Crawford, Inc. | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 05:11 UTC. This page is informational and not investment advice.